Barclays cuts target for Pacific Biosciences stock to USD 1.25

Published on 10/20/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays cut its target to USD 1.25 on October 7, 2026. Pacific Biosciences stock costs EUR 1.78 on October 20, 2026 at Lang & Schwarz.

Analyst target and reporting date

Barclays changed its recommendation on October 7, 2026.
PacBio is scheduled to report third-quarter results on November 4, 2026.
Pacific Biosciences stock costs EUR 1.78 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.

PACB, US69404D1081, Illustration mit AI erstellt.

Barclays cut its Pacific Biosciences target from USD 1.50 to USD 1.25 while keeping a Strong Sell rating on October 7, 2026, according to Zacks. Pacific Biosciences stock was trading at EUR 1.78 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.

Results date is November 4

PacBio is scheduled to report third-quarter 2026 financial results on November 4, 2026. The company listed the earnings conference call for 4:30 p.m. EST on the same date in its investor-relations calendar, according to PacBio. The appointment gives investors a defined date for the next operating update after the second quarter ended June 30, 2026.

Stock valuation remains volatile

On the Nasdaq, PACB was priced at USD 1.98 at 3:37 p.m. ET on October 20, 2026. Its 52-week range was USD 1.07 to USD 3.44, while market capitalization stood at USD 615.4 million at that time. The stock's year-to-date performance was minus 5.61 percent in a separate market snapshot dated October 20, 2026.

What does the target imply?

Barclays' USD 1.25 target sits 36.87 percent below the USD 1.98 Nasdaq price, calculated from the two figures on October 20, 2026. The revised target therefore remains below the latest home-market quotation, while the current euro quotation reflects trading after the Xetra session.

PacBio keeps expanding sequencing work

PacBio develops long-read and short-read sequencing technologies for research and clinical applications, including genomics, oncology and infectious disease work. Its investor-relations page listed a multi-year collaboration with Verily Health dated October 19, 2026, and a collaboration with TychoBio dated October 6, 2026, according to PacBio. Those dates provide recent operating context before the November results.

Price stays below the yearly high

Pacific Biosciences stock remains USD 1.46 below its 52-week high of USD 3.44 on the Nasdaq range dated October 20, 2026. The next major company date is the third-quarter report on November 4, 2026.

Pacific Biosciences was trading at EUR 1.78 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Pacific Biosciences stock.